These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23670184)

  • 1. The role of phosphodiesterases in bladder pathophysiology.
    Rahnama'i MS; Ückert S; Hohnen R; van Koeveringe GA
    Nat Rev Urol; 2013 Jul; 10(7):414-24. PubMed ID: 23670184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.
    Andersson KE; Uckert S; Stief C; Hedlund P
    Neurourol Urodyn; 2007 Oct; 26(6 Suppl):928-33. PubMed ID: 17806124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase 5 mechanisms and therapeutic applications.
    Burnett AL
    Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.
    Yamaguchi O
    Int J Urol; 2013 Jan; 20(1):28-39. PubMed ID: 23190275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
    Montorsi F; Corbin J; Phillips S
    J Sex Med; 2004 Nov; 1(3):322-36. PubMed ID: 16422964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.
    Corbin JD; Francis SH; Webb DJ
    Urology; 2002 Sep; 60(2 Suppl 2):4-11. PubMed ID: 12414329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.
    Saenz de Tejada I; Angulo J; Cuevas P; Fernández A; Moncada I; Allona A; Lledó E; Körschen HG; Niewöhner U; Haning H; Pages E; Bischoff E
    Int J Impot Res; 2001 Oct; 13(5):282-90. PubMed ID: 11890515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic nucleotide signalling compartmentation by PDEs in cultured vascular smooth muscle cells.
    Zhang L; Bouadjel K; Manoury B; Vandecasteele G; Fischmeister R; Leblais V
    Br J Pharmacol; 2019 Jun; 176(11):1780-1792. PubMed ID: 30825186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of phosphodiesterase isoenzymes in the control of human detrusor smooth muscle function. An immunohistochemical and functional study].
    Uckert S; Sigl K; Waldkirch ES; Sandner P; Ulbrich E; Oelke M; Stief CG; Kuczyk MA
    Urologe A; 2009 Jul; 48(7):764-9. PubMed ID: 19352616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: The role of phosphodiesterases in bladder pathophysiology.
    Wein AJ
    J Urol; 2014 Aug; 192(2):488. PubMed ID: 25035014
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro.
    Truss MC; Uckert S; Stief CG; Forssmann WG; Jonas U
    Urol Res; 1996; 24(3):129-34. PubMed ID: 8839479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update.
    Zhang WH; Zhang XH
    Asian J Androl; 2016; 18(5):723-31. PubMed ID: 26620458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle.
    Qiu Y; Kraft P; Craig EC; Liu X; Haynes-Johnson D
    Urology; 2002 Jan; 59(1):145-9. PubMed ID: 11796312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective.
    Bobin P; Belacel-Ouari M; Bedioune I; Zhang L; Leroy J; Leblais V; Fischmeister R; Vandecasteele G
    Arch Cardiovasc Dis; 2016; 109(6-7):431-43. PubMed ID: 27184830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterases do not limit beta1-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1-5 in rats.
    Kaumann AJ; Galindo-Tovar A; Escudero E; Vargas ML
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Nov; 380(5):421-30. PubMed ID: 19693491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization.
    Truss MC; Uckert S; Stief CG; Kuczyk M; Jonas U
    Urol Res; 1996; 24(3):123-8. PubMed ID: 8839478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and functional role of androgen-dependent PDE5 activity in the bladder.
    Filippi S; Morelli A; Sandner P; Fibbi B; Mancina R; Marini M; Gacci M; Vignozzi L; Vannelli GB; Carini M; Forti G; Maggi M
    Endocrinology; 2007 Mar; 148(3):1019-29. PubMed ID: 17138653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase inhibitors for the treatment of erectile dysfunction.
    Küthe A; Montorsi F; Andersson KE; Stief CG
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1489-95. PubMed ID: 12431025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
    Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
    Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.